1. Home
  2. PRPO vs PMN Comparison

PRPO vs PMN Comparison

Compare PRPO & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRPO
  • PMN
  • Stock Information
  • Founded
  • PRPO N/A
  • PMN 2004
  • Country
  • PRPO United States
  • PMN Canada
  • Employees
  • PRPO N/A
  • PMN N/A
  • Industry
  • PRPO Biotechnology: Laboratory Analytical Instruments
  • PMN Pharmaceuticals and Biotechnology
  • Sector
  • PRPO Industrials
  • PMN Health Care
  • Exchange
  • PRPO Nasdaq
  • PMN Nasdaq
  • Market Cap
  • PRPO 22.0M
  • PMN 22.3M
  • IPO Year
  • PRPO N/A
  • PMN N/A
  • Fundamental
  • Price
  • PRPO $17.51
  • PMN $0.46
  • Analyst Decision
  • PRPO
  • PMN Strong Buy
  • Analyst Count
  • PRPO 0
  • PMN 3
  • Target Price
  • PRPO N/A
  • PMN $4.33
  • AVG Volume (30 Days)
  • PRPO 17.3K
  • PMN 872.4K
  • Earning Date
  • PRPO 11-05-2025
  • PMN 11-13-2025
  • Dividend Yield
  • PRPO N/A
  • PMN N/A
  • EPS Growth
  • PRPO N/A
  • PMN N/A
  • EPS
  • PRPO N/A
  • PMN N/A
  • Revenue
  • PRPO $21,242,000.00
  • PMN N/A
  • Revenue This Year
  • PRPO N/A
  • PMN N/A
  • Revenue Next Year
  • PRPO N/A
  • PMN N/A
  • P/E Ratio
  • PRPO N/A
  • PMN N/A
  • Revenue Growth
  • PRPO 27.05
  • PMN N/A
  • 52 Week Low
  • PRPO $3.90
  • PMN $0.38
  • 52 Week High
  • PRPO $22.38
  • PMN $1.59
  • Technical
  • Relative Strength Index (RSI)
  • PRPO 47.44
  • PMN 46.27
  • Support Level
  • PRPO $18.85
  • PMN $0.45
  • Resistance Level
  • PRPO $20.61
  • PMN $0.61
  • Average True Range (ATR)
  • PRPO 1.35
  • PMN 0.04
  • MACD
  • PRPO -0.24
  • PMN 0.01
  • Stochastic Oscillator
  • PRPO 21.35
  • PMN 34.41

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Share on Social Networks: